No news on Pfizer’s Covid-19 vaccine is good news — and bad news
Pfizer and BioNTech are under a white-hot spotlight because their vaccine, by design, is likely to be the first to have any efficacy data.
Pfizer and BioNTech are under a white-hot spotlight because their vaccine, by design, is likely to be the first to have any efficacy data.
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a…
The move by the California Supreme Court to review the case is seen as “very important,” according Evercore ISI analyst Umer Raffat.
The new funding led by General Catalyst and 7wireVentures values Transcarent at $2.2 billion, will be used for AI projects, acquisitions.
Health economist Ben Handel dissects UnitedHealth CEO Andrew Witty’s Senate testimony on the the Change Healthcare cyberattack.
Novo Nordisk on Thursday defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company…
BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it concentrates its resources on an anticipated launch of its pivotal…
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer treatments with a new acquisition.
Measures of biological age have exploded into health research and have fueled hype around consumer tests. But the field of aging has still not settled…
CVS Health missed its Q1 projections and lowered its full-year outlook, citing medical cost hikes with Medicare Advantage patients. Its stock price slid.
The DEA is allowing annual and semi-annual production quotas for Schedule II drugs, after it became clear quarterly quotas would worsen shortages.